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Introduction
Bone structure, adapted to meet the needs of human
mechanics, depends mainly upon the bone turnover,
which occurs throughout the entire life cycle. This is
a modulating process, which allows to develop correct
bone architecture capable of supporting weight and to
repair microlesions. Studies aimed at searching for
markers of bone turnover have drawn attention to protein
molecules and their degradation products are released
during bone turnover. They are said to reflect the activity
of all turnover processes, which are active over a period
of time throughout the entire skeleton, and provide a lot
of valuable data useful both in monitoring the treatment
of bone diseases and in predicting treatment outcome
[1, 2]
Malignant tumors and bone metastases are often
accompanied by imbalance in bone turnover in the form
of increased bone formation and/or resorption. Until now
the prognostic value of these markers had been evaluated
in adult patients with malignancies that metastasize to
the bones [3-5]. Bone metastases are associated with bone
marrow infiltration and expansion of cancer cells, which in
turn activates osteoclasts and promotes osteolysis and/or
osteosclerosis [6]. These processes are accompanied by
altered concentrations of markers of bone formation and
resorption, the most important of which are bone alkaline
phosphatase (BALP), osteocalcin (OC) and C-terminal
cross-linking telopeptide of type I collagen (CTX) [7].
Increased BALP and OC activity has been observed in
breast and prostate cancer patients with bone metastases
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I n t r o d u c t i o n.  Several studies have indicated the clinical utility of specific bone turnover markers in patients with bone
tumors, among them children with osteosarcoma both in the course of diagnosis and for monitoring therapy.  According to the
histological classification there are different subtypes of osteosarcoma. Among them the most frequent is the conventional mixed
subtype in which different patterns are represented.
A i m.  The aim of this study was to investigate selected bone turnover markers in patients with mixed subtype osteosarcoma
during clinical treatment.
S u b j e c t s  a n d  m e t h o d s.  We studied 23 patients (7 girls, 16 boys) at the age 5-20 years with mixed subtype osteosarcoma.
The tested group consisted of 12 patients with favourable (regression) and 11 patients with unfavourable (progression)
prognosis. The levels of osteocalcin (OC), bone alkaline phosphatase (BALP) and the C-terminal cross-linking telopeptide
of type I (CTX) collagen were measured in serum using ELISA kits at diagnosis, during preoperative and postoperative
chemotherapy and after treatment.  
R e s u l t s.  Values of bone turnover markers in patients with favourable and unfavourable prognosis at the moment of
biopsy were similar. During chemotherapy and before treatment the values of OC, BALP and CTX were lower. However, in
patients with unfavourable prognosis, as compared to those with favourable prognosis, the levels of tested parameters were
higher. After clinical treatment the bone formation markers were 3-fold higher and the bone resorption marker was 2-fold higher
in patients with progression, as compared to those with remission. The obtained differences between both groups were
statistically significant for osteocalcin, bone alkaline phosphatase and the C-terminal cross-linking telopeptide of type I
collagen  - p<0.05, p<0.02, p<0.002, respectively.
C o n c l u s i o n s.  Our results suggest, that bone turnover markers may be useful in the monitoring and in the assessment of the
efficacy of therapy in children with mixed subtype osteosarcoma. However, further studies on bone metabolism are necessary
to confirm the prognostic values of bone formation and resorption markers in different subtypes of osteosarcoma.
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[8, 9]. Marchei et al. have reported the high sensitivity
and specificity of BALP in breast cancer patients, as its
increased concentration would precede the development
of scintigraphy-discernible bone metastases by a couple of
months [8]. In the case of prostate cancer patients CTX
serum concentrations were increased by 25% in
metastases-free individuals and were 4 times higher in
individuals with bone metastases, as compared to the
control group [9]. The analysis of cross-linking telo-
peptides seems to be especially useful, as the levels
of both CTX and NTX (N – terminal cross-linking
telopepticle of type  cologen) correlate positively with
the number of metastatic lesions and with cancer
progression [10, 11].
Our studies concerning the usefulness of the markers
of bone formation and resoprtion confirm that they are
good markers of disease progression in the monitoring of
patients with mixed subtypes of osteosarcoma [12, 13].
Increased serum BALP activity and CTX and OC
concentrations may be associated with poor prognosis in
these patients. However these studies had been conducted
on patients with bone sarcomas belonging to different
histologic subtypes. It is well known that osteosarcomas
are a histologically varied group, multipotential as to the
differentiation of mesenchymal stroma. A characteristic
feature of importance in tumor diagnostics is osteoid
and/or bone production directly from the sarcomatic
mesenchymal stroma without cartilage involvement. Thus,
there has developed a whole classification system of
osteosarcoma subtypes depending upon tumor histology.
Among these the most common is the conventional mixed
subtype, in which different structural elements appear
alongside [14].
The aim of this study was to evaluate selected
markers of bone turnover in the course of treatment in
patients with the most common, histologically con-
ventional, mixed subtype of osteosarcoma.
Material and methods
The studied group consisted of 23 patients (7 girls, 16 boys)
aged between 5 and 20 years with a conventional, mixed form of
osteosarcoma treated at the Clinical Department of Paediatric
Oncological Surgery at the Institute of Mother and Child in
Warsaw between the years 1999-2004. The patients were divided
into 2 subgroups:
- a subgroup with good prognosis with disease remission (12
children),
- a subgroup with poor prognosis due to disease progression
during treatment (11 children).
The patients were administered preoperative chemo-
therapy, underwent surgery and then were administered post-
operative chemotherapy. Chemotherapy had been administered
according to an EORTC (adriamycin, cis-platin) or SFOP
(adriamycin, methotrexate, etopozide and ifosfamide) protocols.
All the patients were evaluated for the concentration of bone
formation and resorption markers before treatment onset,
during pre- and postoperative chemotherapy and after the
termination of treatment. The study protocol had been approved
by the ethics committee of Institute of Mother and Child.
Venous blood had been collected from fasting patients in
the morning hours. The serum obtained by centrifugation
(300xg, 4°C, 10 min) was frozen in the temperature of -20°C
until analysis (always under 2 months). OC and CTX mea-
surements were performed immunoenzymatically using the N-
mid Osteocalcin One Step Elisa kit and the Serum CrossLaps
One Step Elisa kit (Osteometer Bio Tech, Denmark). BALP
activity was evaluated using the immunoenzymatic ELISA
method with the Alkphase-B kit (Metra Biosystem, USA).
Statistica 6.0 software had been used for statistical analysis.
Results are presented as median and range (25%-75%). The
significance of the differences was tested with the Mann-Whitney
test. The significance level was set at p<0.05.
Results
Changes of the parameters of bone turnover throughout
the treatment course in relation to prognosis have been
presented in Figures 1, 2 and 3.
At the time of biopsy the concentration of osteo-
calcin was similar in patients with good and poor
prognosis (Figure 1). In the course of preoperative
chemotherapy its serum concentrations fell by 30-35%
in both the groups. During postoperative chemotherapy
these values were increased by 15% in patients with good
prognosis and by as much as 30% in patients with poor
prognosis. After the termination of treatment patients
with good prognosis reported with a similar concentration
of osteocalcin (median 44.2 μg/L), while in the poor
prognosis group this value was approx. three-fold higher
(median 122.8 μg/L; p < 0.05)
In the course of preoperative treatment BALP
activity decreased by 40%, as compared to the values at
diagnosis, and did not undergo any significant changes
in the course of adjuvant chemotherapy. However, after
treatment completion BALP activity was 3 times higher in
the poor prognosis group (median 104,8 U/L; p<0.02)
than in the good prognosis group (median 37.5 U/L)
(Figure 2).
CTX levels decreased by approx. 85% in the course
of preoperative chemotherapy in patients with good
prognosis, then, during postoperative treatment they
increased by some 15% and remained at that level after
treatment completion. In the case of patients with poor
prognosis the decrease during preoperative chemotherapy
was much less significant, approx. 30%, while the increase
during postoperative chemotherapy was also approx. 30%.
After the completion of treatment patients with
progression reported with twofold values of the marker of
bone resorption (median: 15528 pmol/L; p<0.002) as
compared to patients with remission (median: 8195
pmol/L) (Figure 3).
Discussion
We have presented two groups of children with
osteosarcoma – with good and poor prognosis (the latter
have suffered from disease progression during treatment).
We have analyzed the dynamic changes of bone turnover
markers before, during and after treatment. The
concentrations of OC, BALP and CTX before treatment
did not differ significantly between the two groups. In
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the course of preoperative chemotherapy and during its
postoperative phase the levels of all the 3 markers of
bone metabolism decreased significantly in a majority of
patients, although, commonly, they were higher in
patients with poor prognosis, as compared to the patients
with good prognosis. The greatest differences between
the groups were observed after treatment completion. In
patients with progression the levels of the 2 markers of
bone formation were three times as high, while the level
of CTX was twice as high, as compared to patients with
remission. Literature data shows that patients with
prostate, lung, breast cancer and with Ewing’s sarcoma
present an increase in BALP activity [8, 10, 15, 16].
Fontana et al. [9] and Jung et al. [17] have shown that in
patients with prostate cancer high BALP activity correlate
with bone metastases. It has also been reported that the
activity of this enzyme correlates positively not only with
the number of radiologically confirmed metastatic sites,
but also with the degree of disease advancement [8, 16,
18]. These observations and own results obtained from
osteosarcoma patients suggest that in these cases the
process of bone formation may be increased, all the more
so because the second marker of bone formation –
osteocalcin – appears to play a diagnostic role in
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Figure 1. The concentration of OC in patients with favourable (a) and unfavourable (b) prognosis 
during diagnosis (1), preoperative chemotherapy (2), postoperative chemotherapy (3) 
and after treatment (4)
osteosarcoma progression. In the course of previous
immunohistochemical studies Fanburg et al. [19] and
Nagoya et al. [20] have postulated the usefulness of BALP
and OC in the diagnosis of osteosarcoma.
There are also discussions in literature concerning
the prognostic value of bone resorption markers. It seems
that their increased secretion is the effect of intensified
resorption induced by the neoplastic process. In adult
patients with primary tumors of the prostate, lung, breast,
kidney, throat and the alimentary tract the markers of
bone resorption are elevated [8, 15, 21-23]. This is
especially true in patients with metastases, in whom CTX
concentration may be almost 4 times as high as in the
control group [9]. Berruti et al. [10] and Demers et al.
[11] have shown that the bone resorption markers
correlate positively with the number of metastatic sites
and with tumor progression. Body et al. [24] suggest that
the evaluation of the efficacy of anticancer treatment
using the markers of bone resorption may be faster and
more specific than using conventional radiological and
scintigraphic techniques. A decrease in the concentration
of these markers is a symptom of a positive reaction
to treatment, while their increase suggests disease
progression [25]. This is consistent with our findings, both
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Figure 2. The activity of BALP in patients with favourable (a) and unfavourable (b) prognosis 
during diagnosis (1), preoperative chemotherapy (2), postoperative chemotherapy (3) 
and after treatment (4)
previous and those presented in this paper, i.e. regarding
patients with conventional mixed type osteosarcoma [12].
Therefore it is possible that bone resorption markers may
have a prognostic value in children with osteosarcoma, as
is the case with adult osteosarcoma patients. These
observations correspond with those of Ferrari et al. [26],
who have found a higher secretion of bone resorption
markers in urine in osteosarcoma patients. They have
suggested that in children with osteosarcoma intense bone
resorption may be associated with the degree of tumor
aggression. The prognostic value of bone turnover
markers in children and adolescents with different
subtypes of osteosarcoma has never been the subject of
systematic studies. The data presented above shows that
the values of both formation and resorption markers in
patients with a mixed subtype of osteosarcoma often
accompanies disease progression, while their decrease
may suggest a positive reaction to clinical treatment.
These markers could therefore be used not only in the
course of anticancer therapy in order to assess the
response to treatment but also after the completion of
treatment as a part of routine follow-up in order to
discern early stage metastatic tumors. However only
further studies on bone metabolism performed both on
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Figure 3. The concentration of CTX in patients with favourable (a) and unfavourable (b) prognosis 
during diagnosis (1), preoperative chemotherapy (2), postoperative chemotherapy (3) 
and after treatment (4)
cases of mixed subtype and in other subtypes of osteo-
sarcoma may allow to assess the prognostic value of bone
formation and resorption markers.
Conclusions
1. Anticancer treatment administered to children and
adolescents with conventional mixed subtype osteo-
sarcoma may decrease the rate of bone turnover due to
the inhibition bone formation as well as bone
resorption processes.
2. In patients with conventional, mixed subtype osteo-
sarcoma high values of bone formation and resorption
markers during and after treatment are associated with
poor prognosis and may be a sign of disease pro-
gression.
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